Zydus
Zydus Pharmaceuticals is providing refunds for 340B overcharges during 2022 on 83 NDCs.

Zydus Pharmaceuticals USA Announces Refunds for 340B Overcharges During 2022

Generic drug manufacturer Zydus Pharmaceuticals USA said in a recent public notice it will pay refunds for 340B overcharges that occurred mostly in the first two quarters of 2022. The products include Zydus’ equivalents of the widely prescribed antibiotic Zithromax, hyperactivity drug Adderall, hypertension drug Cardizem, and enlarged prostrate and erectile dysfunction treatment Cialis.

The refund notice is dated Feb. 14. The U.S. Health Resources and Services Administration posted it on the Office of Pharmacy Affairs website March 3. It lists 83 Zydus generic drugs spanning a wide range of indications.

Generic drug manufacturer Zydus Pharmaceuticals USA said in a recent public notice it will pay refunds for 340B overcharges that occurred mostly in the first two quarters of 2022.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer